SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
-------------------------------
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
----------------------------------
Date of Report (DATE OF EARLIEST EVENT REPORTED): JULY 2, 2002
------------
ANIKA THERAPEUTICS, INC.
-------------------------------------------------------------------------------
(EXACT NAME OF REGISTRANT AS SPECIFIED IN CHARTER)
MASSACHUSETTS 000-21326 04-3145961
----------------------------- ------------------------ ------------------
(STATE OR OTHER JURISDICTION (COMMISSION FILE NUMBER) (IRS EMPLOYER
OF INCORPORATION) IDENTIFICATION NO.)
236 WEST CUMMINGS PARK, WOBURN, MASSACHUSETTS 01801
-------------------------------------------------------------------------------
(ADDRESS OF PRINCIPAL EXECUTIVE OFFICES) (ZIP CODE)
(781) 932-6616
---------------------
(REGISTRANT'S TELEPHONE NUMBER, INCLUDING AREA CODE)
ITEM 4. CHANGES IN REGISTRANT'S CERTIFYING ACCOUNTANT.
On July 2, 2002, Anika Therapeutics, Inc. (the "Company") selected
PricewaterhouseCoopers LLP as its principal independent auditor for the fiscal
year ending December 31, 2002. Arthur Andersen LLP served as the Company's
principal independent auditor for the fiscal years ended December 31, 2000 and
2001. The decision to engage PricewaterhouseCoopers LLP as the Company's new
principal independent auditor was recommended by the Audit Committee and
approved by the Company's Board of Directors.
During the fiscal years ended December 31, 2000 and 2001 and the subsequent
interim period through June 6, 2002, PricewaterhouseCoopers LLP was not engaged
as either the principal accountant to audit the Company's financial statements
or as an independent accountant to audit any of the Company's consolidated
subsidiaries, nor was PricewaterhouseCoopers LLP consulted by the Company or
someone on its behalf with respect to either (i) the application of accounting
principles to any specific transaction, either completed or proposed, or the
type of audit opinion that might be rendered on the Company's financial
statements or (ii) any matter that was either the subject of a disagreement with
Arthur Andersen LLP or any reportable events described in Items 304(a)(2)(i) and
304(a)(2)(ii) of Regulation S-K, respectively.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.
ANIKA THERAPEUTICS, INC.
Date: July 8, 2002 /s/ Charles H. Sherwood
-----------------------------------
Charles H. Sherwood
Chief Executive Officer and President